Polypharmacology in Clinical Applications—Anticancer Polypharmacology

Wang, Zhiguo; Yang, Baofeng

doi:10.1007/978-3-031-04998-9_3

Cited by 2 publications

(2 citation statements)

References 355 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the realm of pharmaceutical interventions, the Food and Drug Administration (FDA) has granted approval to over 300 chemotherapeutic agents, including nivolumab, ipilimumab, pembrolizumab, 5-flurouracil, Olaparib, taxol, vinca alkaloids, and their derivatives, as well as gemcitabine and methotrexate [6][7][8]. Presently, the majority of Pharmaceuticals 2023, 16, 1617 2 of 24 chemotherapeutic treatments focus on single targets within nucleic acids, proteins, and carcinogenic signaling pathways.…”

Section: Introductionmentioning

confidence: 99%

An Overview of Cancer in Djibouti: Current Status, Therapeutic Approaches, and Promising Endeavors in Local Essential Oil Treatment

Abdoul-Latif,

Ainane,

Houmed Aboubaker

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Djibouti, a developing economy, grapples with significant socioeconomic obstacles and the prevalence of infectious pathologies, including certain forms of neoplasms. These challenges are exacerbated by limited access to affordable medical technologies for diagnosis, coupled with a lack of preventive interventions, particularly in disadvantaged areas. The attention devoted to local phytotherapeutic treatments underscores the uniqueness of Djibouti’s flora, resulting from its distinctive geographical position. International focus specifically centers on harnessing this potential as a valuable resource, emphasizing the phytoconstituents used to counter pathologies, notably carcinomas. This comprehensive overview covers a broad spectrum, commencing with an examination of the current state of knowledge, namely an in-depth investigation of oncological risk factors. Essential elements of control are subsequently studied, highlighting the fundamental prerequisites for effective management. The significance of dietary habits in cancer prevention and support is explored in depth, while traditional methods are examined, highlighting the cultural significance of indigenous essential oil therapies and encouraging further research based on the promising results.

show abstract

Section: Introductionmentioning

confidence: 99%

An Overview of Cancer in Djibouti: Current Status, Therapeutic Approaches, and Promising Endeavors in Local Essential Oil Treatment

Abdoul-Latif,

Ainane,

Houmed Aboubaker

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Medicinal polypharmacology also stretches far into the very basis of drug design, discovery, and development itself (Anighoro et al, 2014; Proschak et al, 2019). Multitarget agents allow not only for addressing multiple druggable targets of the addressable “diseasome” (Wang & Yang, 2022); they also reach into a network of (yet) undruggable targets by either of two ways: (i) impact on a druggable target which subsequently reaches into a network of undruggable targets by a known or unknown pathway; or (ii) direct interaction with the to this point undruggable target itself (Korcsmaros et al, 2007). Multitarget agents are suitable ligands to de‐orphanize undruggable targets: …”

mentioning

confidence: 99%

Medicinal polypharmacology: Exploration and exploitation of the polypharmacolome in modern drug development

Stefan,

Rafehi

2023

Drug Development Research

View full text Add to dashboard Cite

At the core of complex and multifactorial human diseases, such as cancer, metabolic syndrome, or neurodegeneration, are multiple players that cross‐talk in robust biological networks which are intrinsically resilient to alterations. These multifactorial diseases are characterized by sophisticated feedback mechanisms which manifest cellular imbalance and resistance to drug therapy. By adhering to the specificity paradigm (“one target‐one drug concept”), research focused for many years on drugs with very narrow mechanisms of action. This narrow focus promoted therapy ineffectiveness and resistance. However, modern drug discovery has evolved over the last years, increasingly emphasizing integral strategies for the development of clinically effective drugs. These integral strategies include the controlled engagement of multiple targets to overcome therapy resistance. Apart from the additive or even synergistic effects in therapy, multitarget drugs harbor molecular‐structural attributes to explore orphan targets of which intrinsic substrates/physiological role(s) and/or modulators are unknown for future therapy purposes. We designated this multidisciplinary and translational research field between medicinal chemistry, chemical biology, and molecular pharmacology as ‘medicinal polypharmacology’. Medicinal polypharmacology emerged as alternative approach to common single‐targeted pharmacology stretching from basic drug and target identification processes to clinical evaluation of multitarget drugs, and the exploration and exploitation of the ‘polypharmacolome’ is at the forefront of modern drug development research.

show abstract

Polypharmacology in Clinical Applications—Anticancer Polypharmacology

Cited by 2 publications

References 355 publications

An Overview of Cancer in Djibouti: Current Status, Therapeutic Approaches, and Promising Endeavors in Local Essential Oil Treatment

An Overview of Cancer in Djibouti: Current Status, Therapeutic Approaches, and Promising Endeavors in Local Essential Oil Treatment

Medicinal polypharmacology: Exploration and exploitation of the polypharmacolome in modern drug development

Contact Info

Product

Resources

About